Pioglitazone, brand name Actos, is a thiazolidinedione (TZD) that lowers A1C by 1 to 1.5 percent by improving how the body responds to its own insulin. Unlike sulfonylureas, it does not stimulate insulin secretion — and unlike most diabetes drugs, it acts through a genomic mechanism that takes weeks to reach full effect. It is generic and inexpensive, has documented benefits in fatty liver disease, but carries a boxed warning for heart failure and known risks of edema, weight gain, and fractures.
How Pioglitazone Works
Pioglitazone activates PPAR-gamma (peroxisome proliferator-activated receptor gamma), a nuclear receptor found in adipose tissue, skeletal muscle, and liver. PPAR-gamma activation drives gene transcription changes that improve insulin sensitivity, redistribute fat (more subcutaneous, less visceral), reduce hepatic glucose output, and lower circulating free fatty acids.
- Drug class: thiazolidinedione (glitazone)
- Brand name: Actos
- Generic status: yes, widely available
- Onset of action: weeks (genomic mechanism)
- Half-life: 3 to 7 hours for parent; 16 to 24 hours for active metabolites
- Metabolism: hepatic (CYP2C8 primary, CYP3A4 secondary)
- Excretion: bile, then feces
Approved Uses
- Adjunct to diet and exercise in adults with type 2 diabetes
- Monotherapy or combination with metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors, or insulin
- Off-label uses: NAFLD/NASH, polycystic ovary syndrome (insulin resistance component)
- Not used for type 1 diabetes or diabetic ketoacidosis
Typical Dosing
| Population | Starting Dose | Maintenance | Maximum |
|---|---|---|---|
| Adults without HF | 15 to 30 mg once daily | 30 to 45 mg | 45 mg/day |
| NYHA Class I or II HF | 15 mg once daily | Monitor closely; up to 30 mg | 30 mg/day |
| NYHA Class III or IV | Contraindicated | Contraindicated | Contraindicated |
| With strong CYP2C8 inhibitor (gemfibrozil) | 15 mg once daily | 15 mg | 15 mg/day |
Take once daily, with or without food. Titrate every 8 to 12 weeks based on A1C and weight/edema response.
Effect on A1C and Other Outcomes
- A1C reduction: 1.0 to 1.5 percent
- Fasting glucose: 30 to 50 mg/dL reduction
- HDL cholesterol: typically rises 5 to 10 percent
- Triglycerides: typically fall 10 to 20 percent
- LDL cholesterol: small increase, with shift toward less atherogenic particle size
- Insulin resistance: meaningful reductions on HOMA-IR
- Hepatic fat: documented reductions in NASH studies
What the PROactive Trial Showed
The PROactive trial (Dormandy et al., Lancet 2005) randomized 5,238 patients with type 2 diabetes and established macrovascular disease to pioglitazone or placebo on top of standard care. After 3 years:
- Primary composite endpoint (death, MI, stroke, ACS, leg revascularization, leg amputation) was not significantly reduced
- Key secondary endpoint (death, MI, stroke alone) was reduced by 16 percent — statistically significant
- Heart failure events were more common in the pioglitazone arm
- Bladder cancer signal first emerged in this trial
PROactive established pioglitazone as cardiovascular-neutral overall, with possible MACE benefit, balanced against the heart failure signal.
Common Side Effects
- Edema — 5 to 15 percent of users; higher when combined with insulin
- Weight gain — 3 to 5 kg typical, sometimes more; from both fluid retention and adipogenesis
- Upper respiratory infection
- Sinusitis
- Muscle aches
- Headache
Serious Side Effects and Warnings
- Heart failure precipitation — boxed warning; pioglitazone does not damage the heart but can trigger fluid retention that decompensates susceptible patients
- Fracture risk — roughly 2x in postmenopausal women, primarily distal upper and lower limb fractures
- Bladder cancer — small contested signal, particularly with cumulative dose; avoid in active bladder cancer
- Macular edema (rare; check vision)
- Liver enzyme elevations (uncommon at modern doses; baseline LFTs recommended)
- Hypoglycemia rare alone, more common with insulin or sulfonylurea co-administration
- Increased ovulation in premenopausal women with PCOS or anovulation — may resume fertility
Who Should Not Take Pioglitazone
- NYHA Class III or IV heart failure
- Active bladder cancer
- Severe liver disease
- Type 1 diabetes
- Diabetic ketoacidosis
- Pregnancy and breastfeeding
- Macular edema
- Known hypersensitivity
Cautious Use
- NYHA Class I or II heart failure — start low, monitor weight and edema closely
- History of bladder cancer
- Postmenopausal women, especially with osteoporosis risk factors
- Combination with insulin — higher edema and weight gain risk
- Elderly patients
Pioglitazone Compared with Other Insulin Sensitizers
| Feature | Pioglitazone | Metformin |
|---|---|---|
| Mechanism | PPAR-gamma agonist; improves peripheral insulin sensitivity | Reduces hepatic glucose output; modest peripheral effect |
| A1C drop | 1.0 to 1.5% | 1.0 to 1.5% |
| Weight | +3 to 5 kg | Neutral or mild loss |
| Edema | 5 to 15% | Rare |
| Heart failure | Boxed warning | Generally safe |
| Fracture risk | Yes, in postmenopausal women | None |
| NAFLD benefit | Yes, documented | Modest at best |
| Hypoglycemia alone | Rare | Rare |
| Cost/month | ~$10 to $30 generic | ~$4 |
Where Pioglitazone Fits in 2024 Care
The ADA Standards of Care 2024 list pioglitazone as a possible add-on to metformin, particularly when cost is a major concern. It is also worth considering for patients with documented NAFLD/NASH where the off-label benefit may be meaningful. Pioglitazone is not preferred in patients with established cardiovascular disease or heart failure compared with GLP-1 agonists and SGLT2 inhibitors, which carry stronger cardiovascular safety data and weight-favorable profiles.
Monitoring on Pioglitazone
- Weight — weekly self-checks for the first 3 months
- Edema — daily attention; ankle puffiness, shortness of breath
- A1C — every 3 months until stable, then every 6 months
- Liver function tests — at baseline; repeat if jaundice, abdominal pain, or fatigue
- Eye exam — annual; report any vision change
- Bone density — consider in postmenopausal women on long-term therapy
Drug Interactions
- Gemfibrozil — strong CYP2C8 inhibitor; doubles pioglitazone exposure. Limit dose to 15 mg.
- Rifampin — strong CYP2C8 inducer; lowers pioglitazone levels.
- Insulin and sulfonylureas — additive edema, weight gain, hypoglycemia.
- Oral contraceptives — pioglitazone may reduce some hormonal contraceptive levels slightly.
- Diuretics — may be needed for edema management but do not always resolve TZD-related fluid retention.
Practical Tips
- Weigh yourself weekly, especially during the first 3 months
- Watch for ankle swelling and shortness of breath, especially walking up stairs
- Take the same time each day; food does not matter
- Do not start during an acute illness with heart failure features
- If premenopausal and not desiring pregnancy, use reliable contraception (drug can restore ovulation)
- Report any pink or red urine immediately (bladder symptom screening)
- Ask about bone density screening if postmenopausal or already at osteoporosis risk
Related Reading
See our companion guides on pioglitazone side effects in detail, Avandia (rosiglitazone), and the broader treatment overview. The complications and related conditions article gives context on NAFLD and other comorbidities pioglitazone may affect.
The Bottom Line
Pioglitazone (Actos) is a reasonable, inexpensive option for type 2 diabetes when insulin resistance dominates the picture, when cost matters, or when NAFLD or NASH is present. It lowers A1C by 1 to 1.5 percent, improves lipid markers modestly, and can reduce hepatic fat. Trade-offs are real: edema, 3 to 5 kg weight gain, doubled fracture risk in postmenopausal women, and a boxed warning for heart failure precipitation. The bladder cancer signal is small and contested. Modern guidelines prefer GLP-1 agonists or SGLT2 inhibitors in patients with cardiovascular disease, heart failure, or chronic kidney disease, but pioglitazone retains a clear niche. Talk to your clinician about whether the benefits fit your specific situation.
